Evaluating the Measurement Properties of the Self-Assessment of Treatment Version II, Follow-Up Version, in Patients with Painful Diabetic Peripheral Neuropathy
Table 5
Percentage of participants meeting various MID definitions for SAT II follow-up scores at week 12.
SAT II follow-up score
SEM
SEM
0.5 SD
BPI-DN item 5: 30–40%
BPI-DN item 5: 25–35%
BPI-DN item 9F: 30–40%
BPI-DN item 9F: 25–35%
PGIC: minimally improved
PGIC: minimally improved and much improved
Pain improvement
175 (51.62%)
175 (51.62%)
175 (51.62%)
108 (31.86%)
108 (31.86%)
108 (31.86%)
108 (31.86%)
74 (21.83%)
74 (21.83%)
Impact summary
166 (48.97%)
166 (48.97%)
166 (48.97%)
127 (37.46%)
117 (34.51%)
107 (31.56%)
127 (37.46%)
75 (22.12%)
64 (18.88%)
Treatment continuation
292 (86.14%)
292 (86.14%)
292 (86.14%)
123 (36.28%)
123 (36.28%)
123 (36.28%)
123 (36.28%)
123 (36.28%)
123 (36.28%)
Treatment comparison
317 (93.51%)
317 (93.51%)
317 (93.51%)
154 (45.43%)
154 (45.43%)
154 (45.43%)
154 (45.43%)
71 (20.94%)
71 (20.94%)
SEM = SD of the measure multiplied by the square root of 1 minus its reliability coefficient ICC from the test-retest assessment. ICC1: evaluated among stable subjects (BPI-DN item 5 < 20%) between week 8 and week 12. ICC2: evaluated among stable subjects (EQ-5D VAS change < 20%) between week 8 and week 12.
